Michael H. Tomasson, MD (@MTomasson) header
Michael H. Tomasson, MD (@MTomasson) profile picture

Physician-scientist and man about town. Account is personal + does not represent the opinions of the University or Federal Government in any way.

Iowa City, IA
Joined November 2011
Photo by Michael H. Tomasson, MD (@MTomasson)Photo by Michael H. Tomasson, MD (@MTomasson)Photo by Michael H. Tomasson, MD (@MTomasson)Photo by Michael H. Tomasson, MD (@MTomasson)Photo by Michael H. Tomasson, MD (@MTomasson)Photo by Michael H. Tomasson, MD (@MTomasson)Photo by Michael H. Tomasson, MD (@MTomasson)Photo by Michael H. Tomasson, MD (@MTomasson)Photo by Michael H. Tomasson, MD (@MTomasson)Photo by Michael H. Tomasson, MD (@MTomasson)
Cancer prevention fails when infrastructure can’t support longitudinal care. When high-risk patients must leave their health system for “routine” prevention, that’s a systems signal. In hematologic malignancy precursor states (e.g. MGUS, smoldering myeloma), prevention requires embedded biobanking, defined surveillance pathways, and realistic capacity planning. pmc.ncbi.nlm.nih.gov/article… These are catchment & shared-resource issues. Prevention cohorts depend on reliable surveillance access, stable accrual pipelines, and biobanks integrated into clinical operations. When access breaks, accrual breaks—and prevention science stalls
4
5
16
8,369
It’s that ASH time of year when I try to impress on people how stunning progress has been in the blood cancer field. My entire career AL amyloidosis has been a death sentence. Not anymore. I wish the AI biobros all the best but medical miracles are not 10 years in the future—they are here now.
Can AL amyloidosis be cured? Dr. Meletios Dimopoulos at #ISA2026: functional cure = no relapse ≥5 yrs after hemCR, no salvage, no cardiac/dialysis-requiring renal progression. Low clone burden, early deep response and MRD negativity define this group. #mmsm @ISA_Amyloidosis
12
932
Michael H. Tomasson, MD retweeted
1
1
10
728
Michael H. Tomasson, MD retweeted
Rob Sand's anti-party populism.
36
70
40
854
120,598
Michael H. Tomasson, MD retweeted
Abstract 825 (Guan): Dara-Ven-Dex as frontline therapy for t(11;14) AL amyloidosis. Phase 2 study of 38 patients with 10.9 months follow-up. The 3-month CR/VGPR rate was 89%! Best cardiac response was 71% and renal response 80%. 3 cardiac deaths in the first 3 months. My take: I’d much prefer this option for t(11;14) AL amyloidosis over Dara-CyBorD. I like this even over a potential BsAb for more frail patients.
4
9
597
Michael H. Tomasson, MD retweeted
I invite you to enjoy a recent podcast that I recorded that discussed mechanisms for CVD on diabetes. Mins 1:48-3:00, and then minute 30:00 to the end, although I would encourage listening to the whole thing! diabetesbio.libsyn.com/insul…
2
22
954
Michael H. Tomasson, MD retweeted
Are we curing patients with r/r DLBCL using BsAb monotherapy beyond 2L? #ASH26 5-year outcomes with glofitamab: • DoCR: 46% • 5-year PFS: 19.3% • 5-year OS: 28.1% Perhaps the most democratic form of innovation in lymphoma: potentially curative, off-the-shelf, and not dependent on CAR-T infrastructure!
1
4
20
1,584
Michael H. Tomasson, MD retweeted
Masterclass at #ISA2026: @scheinbp reviewed current AL therapy. Take-homes: Dara-VCd is frontline standard (5-yr OS benefit); adapt to organ vulnerability; ASCT role in dara era unresolved; venetoclax/BCMA active at relapse. #mmsm @ISA_Amyloidosis
6
11
702
Michael H. Tomasson, MD retweeted
1/3 Dr. Prem Soman at #ISA2026: when is tissue biopsy still mandatory in the era of non-biopsy ATTR-CM diagnosis? Three scenarios: monoclonal protein present, negative/equivocal PYP with high suspicion, and discordant findings. #mmsm
2
4
5
556
Michael H. Tomasson, MD retweeted
AI’s health advice can be accurate and still make us sicker. This problem requires a new AI safety standard: behavioral benchmarking via @Penn researchers statnews.com/2026/11/10/ai-h…
1
1
509
Someone tell @DarioAmodei he was too slow
1/ The era of 3 years of intensive chemo for adult ALL is ending. Highlights from Dr. Hagop Kantarjian @DrHKantarjian @UTMDAnderson (MD Anderson) at Louisville Hematology Highlights 🧵 #leusm 2/ Ph+ ALL: ponatinib + blinatumomab is the new standard. In ~110 pts: CR 96%, NGS-MRD neg 95%, 5-yr OS ~90%. Transplant is rarely needed. A randomized NEJM trial confirms it: EFS 86% vs 67%. Consider stopping the TKI after ≥5 yrs of PCR- and NGS-MRD negativity. 3/ Ph– B-ALL: half the chemo (8→4 cycles), plus blinatumomab + inotuzumab, with maintenance cut to ~15 mo. 5-yr OS ~90% up to age 60. Transplant only for the highest-risk genomics. 4/ CAR-T belongs in remission or MRD, not active disease. Track NGS-MRD in everyone: even 5 cells per million predicts relapse. And don't ignore the data coming out of China. 5/ On evidence: when the curves are so far apart that "a truck drives through" them, there's no equipoise. Then waiting a decade for a randomized trial has a cost for patients. Watch the full talk: youtu.be/v5NbU3qlBa4?is=uHfR…
260
Breaking: apparently I’m going to Coachella.
1
139
Michael H. Tomasson, MD retweeted
Mind blowing because it's completely false.
This is mind blowing
56
95
6
10,572
1,161,123
Michael H. Tomasson, MD retweeted
7/10 MajesTEC-5 (Arm G): Frontline trispecific ramantamig + Dara/Len hits 100% ORR & 100% MRD-neg (10^-5) by C3 in TE-NDMM.
1
2
4
230
Michael H. Tomasson, MD retweeted
5/10 NEXICART-2: NXC-201 CAR-T delivers 100% ongoing CR (>12m f/u) & 100% cardiac/renal responses in RR AL amyloidosis.
1
1
2
279
Michael H. Tomasson, MD retweeted
As #ASH26 approaches, I’m bringing back my classic series of tweets highlighting abstracts that matter to physicians working in “the land of NO CAR-T cells.” Because years go by, but some things never change…
3
20
2,329
Hilarious and unexpectedly moving. 5 stars.
“He does extraordinary things in extraordinary ways with brilliant people." Martin McDonagh's WILD HORSE NINE. Now playing only in theaters. Get tickets now.

39